Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patients Offer Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (PO-RAFAELO) Study under the Patient-proposed Health Services.
Takayama S, Kinoshita T, Shiino S, Jimbo K, Watanabe KI, Fujisawa T, Yamamoto N, Onishi T, Shien T, Ito M, Takahashi M, Futamura M, Aruga T, Kaneko K, Suto A. Takayama S, et al. Among authors: futamura m. JMA J. 2023 Oct 16;6(4):505-512. doi: 10.31662/jmaj.2023-0047. Epub 2023 Oct 2. JMA J. 2023. PMID: 37941717 Free PMC article. Clinical Trial.
Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
Nagahashi M, Ling Y, Toshikawa C, Hayashida T, Kitagawa Y, Futamura M, Kuwayama T, Nakamura S, Yamauchi H, Yamauchi T, Kaneko K, Kanbayashi C, Sato N, Tsuchida J, Moro K, Nakajima M, Shimada Y, Ichikawa H, Lyle S, Miyoshi Y, Takabe K, Okuda S, Wakai T. Nagahashi M, et al. Among authors: futamura m. Breast Cancer. 2023 Jul;30(4):584-595. doi: 10.1007/s12282-023-01449-2. Epub 2023 Mar 17. Breast Cancer. 2023. PMID: 36930419
Actionable gene alterations in an Asian population with triple-negative breast cancer.
Nagahashi M, Ling Y, Hayashida T, Kitagawa Y, Futamura M, Yoshida K, Kuwayama T, Nakamura S, Toshikawa C, Yamauchi H, Yamauchi T, Kaneko K, Kanbayashi C, Sato N, Miyoshi Y, Tsuchida J, Nakajima M, Shimada Y, Ichikawa H, Lyle S, Takabe K, Okuda S, Wakai T. Nagahashi M, et al. Among authors: futamura m. JCO Precis Oncol. 2018;2:PO.17.00211. doi: 10.1200/po.17.00211. Epub 2018 Jul 23. JCO Precis Oncol. 2018. PMID: 32529167 Free PMC article.
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, Takahashi M, Futamura M, Matsumoto K, Aogi K, Iwata H, Hosonaga M, Mukohara T, Yoshimura K, Imamura CK, Miura S, Yamochi T, Kawabata H, Yasojima H, Tomioka N, Yoshimura K, Takano T. Masuda J, et al. Among authors: futamura m. J Immunother Cancer. 2023 Sep;11(9):e007126. doi: 10.1136/jitc-2023-007126. J Immunother Cancer. 2023. PMID: 37709297 Free PMC article. Clinical Trial.
Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study).
Futamura M, Oba M, Masuda N, Bando H, Okada M, Yamamoto Y, Kin T, Saeki T, Nagashima T, Kuwayama T, Toh U, Hirano A, Inokuchi M, Yamagami K, Mizuno Y, Kojima Y, Nakayama T, Yasojima H, Ohno S. Futamura M, et al. Breast Cancer. 2021 Sep;28(5):1023-1037. doi: 10.1007/s12282-021-01238-9. Epub 2021 Apr 3. Breast Cancer. 2021. PMID: 33811599 Free PMC article.
Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, Kawabata H, Masuda N, Futamura M, Minami H, Matsumoto K, Yoshimura K, Kitano S, Takano T. Ozaki Y, et al. Among authors: futamura m. Eur J Cancer. 2022 Aug;171:193-202. doi: 10.1016/j.ejca.2022.05.014. Epub 2022 Jun 18. Eur J Cancer. 2022. PMID: 35728379 Free article. Clinical Trial.
Oncofertility-related psycho-educational therapy for young adult patients with breast cancer and their partners: Randomized controlled trial.
Koizumi T, Sugishita Y, Suzuki-Takahashi Y, Nara K, Miyagawa T, Nakajima M, Sugimoto K, Futamura M, Furui T, Takai Y, Matsumoto H, Yamauchi H, Ohno S, Kataoka A, Kawai K, Fukuma E, Nogi H, Tsugawa K, Suzuki N. Koizumi T, et al. Among authors: futamura m. Cancer. 2023 Aug 15;129(16):2568-2580. doi: 10.1002/cncr.34796. Epub 2023 Apr 21. Cancer. 2023. PMID: 37082910 Clinical Trial.
Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.
Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Kitagawa Y, Tsuchiya M, Kitahora M, Nagayama A, Kosaka S, Asano-Niwa Y, Seki T, Ohnuki K, Suzuki A, Ono F, Futamura M, Kawazoe H, Nakamura T. Takahashi K, et al. Among authors: futamura m. Oncologist. 2024 Jun 3;29(6):e741-e749. doi: 10.1093/oncolo/oyae015. Oncologist. 2024. PMID: 38340010 Free article.
Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T, Kurozumi S, Nozawa K, Ozaki Y, Maeda T, Yazaki S, Onishi M, Fujimoto A, Nakayama S, Tsuboguchi Y, Iwasa T, Sakai H, Ogata M, Terada M, Nishimura M, Onoe T, Masuda J, Kurikawa M, Isaka H, Hagio K, Shimomura A, Okumura Y, Futamura M, Shimokawa M, Takano T. Yokoe T, et al. Among authors: futamura m. Breast Cancer. 2021 May;28(3):581-591. doi: 10.1007/s12282-020-01192-y. Epub 2021 Jan 2. Breast Cancer. 2021. PMID: 33389616 Free PMC article.
225 results